References

Critical role for a high-plasticity cell state in lung cancer

10.1038/s41586-025-09985-x · 2026 · External reference

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

10.1038/s41571-020-0340-z · 2020 · External reference

EMT

10.1016/j.cell.2016.06.028 · 2016 · External reference

Hallmarks of cancer: new dimensions

10.1158/2159-8290.cd-21-1059 · 2022 · External reference

Otto Warburg’s contributions to current concepts of cancer metabolism

10.1038/nrc3038 · 2011 · External reference

Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells

10.1016/j.cmet.2015.02.002 · 2015 · External reference

Metabolic switching and cell fate decisions: implications for pluripotency, reprogramming and development

10.1016/j.gde.2017.06.008 · 2017 · External reference

The global burden of lung cancer: current status and future trends

10.1038/s41571-023-00798-3 · 2023 · External reference

Cellular plasticity and regenerative mechanisms in the lung

10.1183/16000617.0168-2025 · 2026 · External reference

Emergence of a high-plasticity cell state during lung cancer evolution

10.1016/j.ccell.2020.06.012 · 2020 · External reference

An atlas of epithelial cell states and plasticity in lung adenocarcinoma

10.1038/s41586-024-07113-9 · 2024 · External reference

A developmental constraint model of cancer cell states and tumor heterogeneity

10.1016/j.cell.2024.04.032 · 2024 · External reference

Comprehensive molecular profiling of lung adenocarcinoma

10.1038/nature13385 · 2014 · External reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

10.1038/nature05945 · 2007 · External reference

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up*

10.1016/j.annonc.2022.12.009 · 2023 · External reference

Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy

10.3390/cancers12030731 · 2020 · External reference

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes

10.1016/j.jtho.2019.06.002 · 2019 · External reference

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

10.1016/s1535-6108(03)00220-4 · 2003 · External reference

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

10.1038/ncomms7377 · 2015 · External reference

Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: a pooled analysis with an additional case

10.1016/j.lungcan.2018.11.016 · 2019 · External reference

Molecular landscape and therapeutic strategies of lung cancer lineage plasticity

10.1016/j.jtho.2025.06.012 · 2025 · External reference

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

10.1038/ncomms14922 · 2017 · External reference

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment

10.21037/tlcr-21-536 · 2021 · External reference

Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation

10.1158/2159-8290.cd-20-1863 · 2021 · External reference

Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas

10.1200/jco.2016.71.9096 · 2017 · External reference

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

10.1038/s41467-018-06162-9 · 2018 · External reference

Significantly mutated genes and regulatory pathways in SCLC—a meta-analysis

10.1016/j.cancergen.2017.05.003 · 2017 · External reference

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

10.21037/tlcr-20-372 · 2020 · External reference

ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?

10.2217/pme-2017-0069 · 2018 · External reference

Genomic and transcriptomic analysis of neuroendocrine transformation in ALK-rearranged lung adenocarcinoma after treatments with sequential ALK inhibitors: a brief report

10.1016/j.jtocrr.2022.100338 · 2022 · External reference

FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer

10.7554/elife.38579 · 2018 · External reference

Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma

10.1101/gad.352742.125 · 2025 · External reference

Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer

10.1126/sciadv.abc2578 · 2021 · External reference

USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity

10.1186/s12943-023-01892-x · 2023 · External reference

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer

10.1038/s41556-021-00743-5 · 2021 · External reference

Epigenetic modulations and lineage plasticity in advanced prostate cancer

10.1016/j.annonc.2020.02.002 · 2020 · External reference

Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling

10.1158/1078-0432.ccr-24-0466 · 2024 · External reference

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer

10.1073/pnas.2317790121 · 2024 · External reference

Structural basis for PRC2 engagement with chromatin

10.1016/j.sbi.2020.10.017 · 2021 · External reference

EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway

10.1038/celldisc.2015.26 · 2015 · External reference

EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization

10.1038/s41388-022-02375-x · 2022 · External reference

Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer

10.1371/journal.pone.0071670 · 2013 · External reference

KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition

10.1038/s41418-025-01657-7 · 2026 · External reference

Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1

10.1038/s41467-022-31998-7 · 2022 · External reference

The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis

10.1101/gad.328336.119 · 2019 · External reference

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

10.1126/scisignal.aau2922 · 2019 · External reference

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

10.1016/s0065-230x(02)86002-x · 2002 · External reference

Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution toward small-cell lung cancer

10.1158/1078-0432.ccr-24-0160 · 2024 · External reference

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

10.1200/jco.2011.38.9411 · 2012 · External reference

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer

10.1111/cas.14260 · 2020 · External reference

Epigenetic switch between SOX2 and SOX9 regulates cancer cell plasticity

10.1158/0008-5472.can-15-3178 · 2016 · External reference

AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces profound and persistent cell state differentiation and inhibits growth in SCLC model systems

10.1016/j.jtho.2025.07.035 · 2025 · External reference

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

10.1182/blood-2025-6952 · 2025 · External reference

Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer

10.3389/fonc.2021.647559 · 2021 · External reference

Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis

10.1186/s12967-023-04403-0 · 2023 · External reference

LDOC1 connects histone H2B monoubiquitination to tumor cell plasticity in non-small cell lung cancer

10.1186/s12964-025-02607-z · 2026 · External reference

Histone H4K12 lactylation promotes malignancy progression in triple-negative breast cancer through SLFN5 downregulation

10.1016/j.cellsig.2024.111468 · 2024 · External reference

Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy

10.3389/fphar.2022.935536 · 2022 · External reference

Metabolic reprogramming of stem cell epigenetics

10.1016/j.stem.2015.11.012 · 2015 · External reference

miR-290/371-Mbd2-Myc circuit regulates glycolytic metabolism to promote pluripotency

10.15252/embj.201490441 · 2015 · External reference

Metabolic heterogeneity in human lung tumors

10.1016/j.cell.2015.12.034 · 2016 · External reference

PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

10.1073/pnas.2416882121 · 2024 · External reference

Intrinsic electrical activity drives small-cell lung cancer progression

10.1038/s41586-024-08575-7 · 2025 · External reference

ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers

10.1172/jci168670 · 2023 · External reference

Lactate controls cancer stemness and plasticity through epigenetic regulation

10.1016/j.cmet.2025.01.002 · 2025 · External reference

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity

10.1126/scitranslmed.adw4689 · 2026 · External reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

10.1038/nature09132 · 2010 · External reference

Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas

10.1038/s43018-024-00865-3 · 2025 · External reference

PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis

10.1016/j.celrep.2017.05.067 · 2017 · External reference

High expression of PHGDH predicts poor prognosis in non-small cell lung cancer

10.1016/j.tranon.2016.08.003 · 2016 · External reference

PSPH mediates the metastasis and proliferation of non-small cell lung cancer through MAPK signaling pathways

10.7150/ijbs.29203 · 2019 · External reference

CD44 regulates epigenetic plasticity by mediating iron endocytosis

10.1038/s41557-020-0513-5 · 2020 · External reference

A druggable copper-signalling pathway that drives inflammation

10.1038/s41586-023-06017-4 · 2023 · External reference

Ferroptosis: an iron-dependent form of nonapoptotic cell death

10.1016/j.cell.2012.03.042 · 2012 · External reference

Copper induces cell death by targeting lipoylated TCA cycle proteins

10.1126/science.abf0529 · 2022 · External reference

An overview of autophagy: morphology, mechanism, and regulation

10.1089/ars.2013.5371 · 2014 · External reference

LC3A-mediated autophagy regulates lung cancer cell plasticity

10.1080/15548627.2021.1964224 · 2022 · External reference

Methionine restriction reduces lung cancer progression and increases chemotherapy response

10.1101/2024.06.25.599795. · 2024 · External reference

Tumour hypoxia in driving genomic instability and tumour evolution

10.1038/s41568-024-00781-9 · 2025 · External reference

HIF1α and HIF2α regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions

10.1016/j.gene.2023.147288 · 2023 · External reference

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer

10.1038/s41467-021-24537-3 · 2021 · External reference

Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression

10.1038/s41419-022-04514-4 · 2022 · External reference

Insights into androgen receptor action in lung cancer

10.3390/endocrines4020022 · 2023 · External reference

Androgen receptor regulates lung cancer progress through modulation of OCT-4 expression

10.1158/1538-7445.am2011-2126 · 2011 · External reference

A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma

10.1038/nature22334 · 2017 · External reference

Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma

10.1016/j.celrep.2023.112212 · 2023 · External reference

Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling

10.1038/ncomms4472 · 2014 · External reference

Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer

10.1038/s41598-024-52687-z · 2024 · External reference

LKB1 modulates lung cancer differentiation and metastasis

10.1038/nature06030 · 2007 · External reference

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer

10.1038/s42255-020-00316-0 · 2020 · External reference

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer

10.1038/s42255-024-01066-z · 2024 · External reference

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach

10.1186/s13046-018-0954-5 · 2018 · External reference

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin

10.1016/j.ccr.2012.12.008 · 2013 · External reference

LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response

10.1016/j.ccell.2015.04.001 · 2015 · External reference

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

10.1016/j.ccell.2024.01.012 · 2024 · External reference

TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition

10.1084/jem.20240111 · 2024 · External reference

In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance

10.1053/j.gastro.2020.08.016 · 2020 · External reference

Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations

10.1038/s42003-026-09543-9 · 2026 · External reference

Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications

10.1016/j.ccell.2025.12.009 · 2026 · External reference

Spatially resolved epigenomic profiling of single cells in complex tissues

10.1016/j.cell.2022.09.035 · 2022 · External reference

Spatial-CUT&Tag: spatially resolved chromatin modification profiling at the cellular level

10.1126/science.abg7216 · 2022 · External reference

Spatial profiling of chromatin accessibility in mouse and human tissues

10.1038/s41586-022-05094-1 · 2022 · External reference